GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Price-to-Owner-Earnings

Financiere de Tubize (LTS:0D53) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Price-to-Owner-Earnings?

As of today (2024-06-09), Financiere de Tubize's share price is €105.40. Financiere de Tubize does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Financiere de Tubize's Price-to-Owner-Earnings or its related term are showing as below:


LTS:0D53's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Financiere de Tubize's share price is €105.40. Financiere de Tubize's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €1.98. Therefore, Financiere de Tubize's PE Ratio for today is 53.23.

As of today (2024-06-09), Financiere de Tubize's share price is €105.40. Financiere de Tubize's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.12. Therefore, Financiere de Tubize's PE Ratio without NRI for today is At Loss.

During the past 13 years, Financiere de Tubize's highest PE Ratio without NRI was 47.34. The lowest was 0.00. And the median was 0.00.


Financiere de Tubize Price-to-Owner-Earnings Historical Data

The historical data trend for Financiere de Tubize's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Price-to-Owner-Earnings Chart

Financiere de Tubize Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Financiere de Tubize Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Financiere de Tubize's Price-to-Owner-Earnings

For the Biotechnology subindustry, Financiere de Tubize's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Financiere de Tubize's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Financiere de Tubize's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Financiere de Tubize's Price-to-Owner-Earnings falls into.



Financiere de Tubize Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Financiere de Tubize's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=105.40/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Financiere de Tubize  (LTS:0D53) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Financiere de Tubize Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Financiere de Tubize (LTS:0D53) Business Description

Traded in Other Exchanges
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize (LTS:0D53) Headlines

No Headlines